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Abstract. The work presents remote results of using 
aldosterone in complex treatment of patients with myocar-
dial infarction combined with heart failure. It is shown that 
after using of eplerenone the authenticity of renewal func-
tional indexes of myocardium becomes higher. 
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Introduction. One of the important issues of 
treatment of patients with myocardial infarction (MI) 
and heart failure (HF) is not only an infarction zone 
stabilization, prevention of progression and death, 
but also prophylaxis of the changes that can lead to 
deterioration of the patient's life [2, 3, 6]. This is 
achieved by reasonable influence on the main 
mechanisms of development of myocardial infarc-
tion and its complications in the early stages of its 
emergence, stabilization of functional parameters of 
the cardiovascular system and creation of conditions 
for the lost functions restoration or optimum adapta-
tion and compensation in the changed conditions of 
the cardiovascular system functioning [1, 13, 15]. 
Material and methods. Study group consisted 
of 24 people who were hospitalized in the intensive 
care unit in Chernivtsi regional cardiology clinic 
with acute Q- MI with signs of acute heart failure 
Killip I-II class, followed by the formation of CH I- 
IIA stage on a long-term observation (1 year) stage. 
The diagnosis was verified according to recommen-
dations of the Association of Cardiologists of 
Ukraine (2012). The average age of patients was 
52,1±3,83 years. All patients were divided into two 
clinical groups: for 14 patients, who formed group I, 
in the basic therapy a nonselective aldosterone an-
tagonist (AA) spironolactone (registration number T 
011 953 / 01 02.09.05g) was included with a daily 
dose of 25 mg; the second group consisted of 10 
patients who received basic therapy in addition with 
selective AA eplerenone (registration certificate № 
UA/3752/0101, UA/3752/01/02 from 09.11.2005g ), 
the dose was 25 mg per day [8, 17]. The definition of 
parameters of the functional state of myocardium 
was performed by using echocardiography in the 
parasternal and apical positions on the long and short 
axes with further calculation of cardiac hemodynam-
ics indicators and evaluation of end-diastolic left 
ventricular size (LVDV), end-systolic size of the left 
ventricle (LVSV), the thickness of interventricular 
septum in diastole (STd), the thickness of left ven-
tricular posterior wall in diastole (LVd PWT). Ac-
cording to the formulas of L.E. Teicholz, a set of 
indicators were calculated: left ventricular end-
diastolic volume (EDV), end-systolic volume (ESV), 
stroke volume (SV), the ejection fraction (EF), left 
ventricular myocardial mass (MM) and LV myocar-
dial mass index (MMI) [4, 5, 16]. Besides general 
clinical and instrumental examinations, an enzyme 
immunoassay for all patients was conducted for the 
determination of hormone levels such as aldosterone, 
angiotensin-converting factor (APF), atrial natri-
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TOTAL FIBRINOGEN LEVEL AS A FACTOR OF CARDIOVASCULAR RISK IN PATIENTS  
WITH HYPERTONIC DISEASE AND OVERWEIGHT 
L.M. Strilchuk  
Abstract. Chronic systemic inflammation is a key component of atherogenesis, whereas increased rate of total fi-
brinogen serves as an independent predictor of ischemic heart disease and additional factor of cardiovascular risk. Our in-
vestigation included 53 patients with hypertonic disease and overweight. It was revealed that total fibrinogen rate was pro-
portional to cardiovascular risk, duration of arterial hypertension, severity of anemia, dyslipidemia, hypertrophy and dilata-
tion of left ventricle. Total fibrinogen rate was inversely proportional to systolic function of left ventricle. In patients with 
increased total fibrinogen more severe right ventricle hypertrophy was revealed.  
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Table 1 
Echocardiography indicators dynamics in patients with myocardial infarction and  
heart failure during the treatment 
Note: * odds ratio - p <0.05; ** - <0.01; *** - <0.001 (shown only statistically probable deviations) 
№ Indicator 










ment After a year 
1 2 3 4 5 6 
1 DV (cm) 4,88±0,28 4,91±0,17 4,96±0,27 4,83±0,18 5,05±0,21 5,02±0,18 
2 SV (cm) 3,53±0,21 3,49±0,18 3,69±0,10 3,49±0,15 3,32±0,26 3,31±0,16 
3 SSd (cm) 1,01±0,08 1,07±0,05 1,02±0,02 1,02±0,06 0,97±0,08 1,03±0,04 
4 LVd PWT(cm) 0,98±0,09 1,09±0,05 0,91±0,12 1,08±0,06 0,96±0,11 1,08±0,04 









6 ESV (ml) 53,75±7,28 52,35±6,70 58,93±8,11 51,56±5,14 47,19±8,66 44,97±5,59 р-3-6* 
7 SV (ml) 61,15±9,33 62,58±6,88 59,94±5,68 58,96±5,72 75,69±8,36 р-4-5** 
76,73±6,76 
р-5-6** 
8 EF (%) 53,26±3,02 55,46±3,93 50,28±2,83 53,43±2,27 62,72±4,74 р-3-5*р-4-5* 
63,71±2,87 
р-3-6*р-4-6* 
9 LVMM (gr) 179,91±21,49 201,73±17,45 179,09±13,22 190,31±16,69 183,51±22,04 203,31±15,99 




uretic peptide (ANP) and von Willebrand factor 
(vWF) [11,12]. Statistical analysis was performed 
using Microsoft ® Office Excel spread sheets (build 
11.5612.5703) and program for statistical processing 
Statgraphics Plus5.1 Enterprise edition (® Statistical 
Graphics corp. 2001). We used the theory of chance 
for the prognosis of the disease, determination of the 
probability of occurrence of expected events in pa-
tients with different output parameters [14, 17]. A P-
value<0.05 was considered statistically significant. 
Results of research and their discussion. Af-
ter analysis of echocardiographic indicators it was 
found that patients in both groups showed improve-
ment of myocardial functional parameters (Table 1). 
It was also identified that DAC increased signifi-
cantly after using spironolactone, and decreased after 
the use of eplerenone.  
EF while using spironolactone decreased after a 
year by 5,6 %, while using eplerenone increased by 
16,1 %, what significantly exceeds this rate for those 
in the first group (p<0,05). SV a year after the treat-
ment was changing differently in both groups. 
Thus, in group I indicator decreased by 1,9 %, 
while in II – grew by 23,2 % (p<0,01). Thickness of 
PWLVd and IVMd changed not statistically signifi-
cantly. To assess the effectiveness of the combined 
treatment with selective and nonselective AA, the 
chance theory was used to analyze the probability of 
echocardiography parameter’s changes (Table 2). It 
was found that the use of eplerenone in patients 
shows a reasonable likelihood of EF increase over 
60,05±5,28 % compared with spironolactone 
(t=2,23, p<0,05 ), and therefore it is obvious that 
selective AA have bigger advantage to restore the 
impaired myocardial contractility after myocardial 
infarction [9, 12]. However, it is aldosterone, exces-
sive concentration of which was observed in MI, 
determines morphological and functional disorders, 
the progression of which is interrupted more effec-
tively by using selective AA. 
Estimation of left ventricular hypertrophy re-
gression (LVH) probability a year after hospital 
treatment revealed different effects of investigated 
drugs. Thus, while using the Eplerenone, the prob-
ability of achieving indicator for LVMM is less 
180,24±15,24 gr significantly higher than while us-
ing Spironolactone (t=2,10, p<0,05). The same regu-
larity is observed for LVMMI – the probability of its 
decline is probable higher with Eplerenone (t=2,75, 
p<0,01). Application of Eplerenone in patients one 
year after myocardial infarction (MI) showed a sig-
nificant LVMM <180,24±15,24 gr and probability 
decrease of ESV less 50,23±5,14 ml (t=2,101, 
p<0,05). Influence on the probability of various AA 
changes of SV is also different – it has been detected 
a reasonable likelihood of SV growth over 
60,24±6,73 ml while using Eplerenone in compara-
sion with Spironolactone (t=2,23, p<0,05). In the 




The influence of eplerenone / spironolactone on echocardiography indicators changes  
in patients with myocardial infarction one year after hospital treatment 
№ Indicator t P 
1 The Ejection fraction (%) >60,05±5,28 / ≤60,05±5,28 2,23 <0,05 
2 LVMM (gr) <180,24±15,24 / ≥180,24±15,24 2,10 <0,05 
3 LVMMI (gr/m²) <95,22±6,87 / ≥95,22±6,87 2,75 <0,01 
4 EDV (ml) >120,74±11,23 / ≤120,74±11,23 2,10 <0,05 
5 ESV (ml) <50,23±5,14 / ≥50,23±5,14 2,10 <0,05 
6 SV (ml) >60,24±6,73 / ≤60,24±6,73 2,23 <0,05 
7 ТLVdPWT (cm) <1,09±0,03 / ≥1,09±0,03 1,49 >0,05 
8 SSd (cm) <1,01±0,05 / ≥1,01±0,05 0,14 >0,05 
Table 3 
Dynamics of neurohumoral regulation indicators in patients with myocardial infarction  
and heart failure in a year 
Note: * – the coefficient of probability – p<0,05; ** – <0,01; *** – <0,001 (shown only statistically probable deviations) 
Table 4 
Influence of Eplerenone/ Spironolactone on changes of neurohumoral messenger’s parameters  
in patients with myocardial infarction and heart failure a year after hospital treatment 
analysis of neurohumoral messengers level which are 
actively involved in the regulation of cardiovascular 
activity and realization of compensatory-adaptive 
mechanisms, it was found (Table 3) that the dynam-
ics of hormones in both groups is aimed at signifi-
cant reduction.  
The analysis of aldosterone concentration in 
blood plasma found that its content decreased sig-
nificantly in both groups (Table 4) after a year, al-
though more expressed in patients treated with 
Eplerenone (p<0,01). Prolonged effect of aldosterone 
concentration reduction, in our opinion, is due to the 
fact that timely and effective blocking of the hor-
№ Indicator 
Control Group І Group ІІ 
1 
2 3 4 5 
Before treat-
ment In a year 
Before treat-
ment In a year 































№ Indicator t p 
1 Aldosterone (pmole/l) ≤149,36±10,26 / >149,36±10,26 2,10 <0,05 
2 Angiotenzinconverting factor (mcmole/min/l) ≤ 50,22±2,57 / >50,22±2,57 2,29 <0,05 
3 Natriuretic peptide (pgr/ml) ≤28,62±5,19 / >28,62±5,19 2,75 <0,01 
4 vWF (gr/l) ≤0,54±0,03 / >0,541±0,03 1,49 >0,05 
mone excessive synthesis and the prevention of its 
action on receptors makes it possible to interrupt the 
ways of its synthesis initiation, implementation dam-
aging effect on the cardiovascular system, as well as 
break the pathological range of mutual hormones 
stimulation. A proof of this is the dynamic of ACE 
concentration - the main initiator of aldosterone syn-
thesis, which decreased significantly in both groups 
of patients in a year, but more expressed and reliable 
in patients treated with Eplerenone.  
Decrease of aldosterone concentration in blood 
plasma during this period was also accompanied by a 
decrease of NUP level which provides the opposite 
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effect – it stimulates natriuresis and decreases blood 
volume. Typically, the concentration of NUP in pa-
tients of Group II is almost two times lower than in 
Group I (p <0.001). Despite the fact that the synthe-
sis of NUP is initiated by irritation of atrium baro- 
and chemoreceptors with rise of circulating blood 
volume, increase of pressure in the atrial cavities 
with preload growth, such concentration dynamics of 
this neuromessenger and humoral regulator of water 
and electrolyte balance is a confirmation of reduce-
ment of heart failure progression. This has been 
achieved in patients by eliminating the pathogenic 
effect of the excessive aldosterone concentration 
growth by the use of the selective aldosterone an-
tagonist [12]. Concentrations of vWF – one of the 
most important regulators of the coagulation homeo-
stasis and markers of endothelial dysfunction [7, 10], 
also decreased significantly, and more expressed – in 
patients treated with Eplerenone. Statistical analysis 
of the effectiveness of AA using chance theory sug-
gests that in patients in the combined treatment with 
myocardial infarction with heart failure was included 
eplerenone, there is a higher probability of reducing 
the level of aldosterone in physiological parameters 
compared with patients treated with spironolactone 
(t=2,10; p<0,05). Chances of a significant reduction 
in such patients, the concentration of ACE also sig-
nificantly higher (t=2,29, p<0,05), as the probability 
of a significant reduction in the concentration of 
ANP (t=2,75, p<0,01). Statistical analysis of the ef-
fectiveness of AA using chance theory suggests that 
in patients who underwent combined treatment of 
myocardial infarction with heart failure, including 
Eplerenone, there is a higher probability of reducing 
the aldosterone level in physiological parameters 
compared with patients treated with Spironolactone 
(t=2,10; p<0,05). Chances of ACF significant reduc-
tion in such patients are also significantly higher 
(t=2,29, p<0,05), as the probability of a significant 
reduction in the concentration of NUP (t=2,75, 
p<0,01). Thus, studies have shown a higher effi-
ciency of the selective AA Eplerenone in the aspect 
of improvement in dynamics of neurohormonal mes-
sengers and functional state of the myocardium in 
the remote follow-up period in patients with MI 
treatment. 
 Conclusions 
1. Coronary incident in the form of myocardial 
infarction with heart failure associated with activa-
tion of neurohumoral messengers having a substan-
tial effect on the functional state of the myocardium 
even in remote periods of observation. 
2. Use of aldosterone antagonists in the treat-
ment of patients with myocardial infarction with 
heart failure in a year helps to reduce the activity of 
neurohumoral messengers, to recover the functional 
state of the myocardium parameters; and the more 
effective selective aldosterone antagonist is 
Eplerenone. 
3. It was found that the probability of myocar-
dial contractility and cardiac pump function im-
provement, reduction of myocardial mass during the 
year using Eplerenone in patients with acute myocar-
dial infarction. 
Prospect of further researches. There will be 
an investigational level of vazopresin at the heart 
attack of myocardium and correlation from vazoac-
tive hormones. 
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МИОКАРДА С СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ 
В.К. Тащук, О.И. Гулага, О.С. Полянская, И.С. Попова 
Резюме. В работе приведены отдаленные результаты использования антагонистов альдостерона в комплекс-
ном лечении больных инфарктом миокарда с сердечной недостаточностью. Показано, что при использовании эпле-
ренона более высокая вероятность восстановления функциональных показателей миокарда. 
Ключевые слова: инфаркт миокарда, сердечная недостаточность, альдостерон, ангиотензин-превращающий 
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АЛЬДОСТЕРОНУ В КОМПЛЕКСНОМУ ЛІКУВАННІ ХВОРИХ НА  
ІНФАРКТ МІОКАРДА З СЕРЦЕВОЮ НЕДОСТАТНІСТЮ 
В.К. Тащук, О.І. Гулага, О.С. Полянська, І.С. Попова 
Резюме. У роботі наведені віддалені результати використання антагоністів альдостерону в комплексному 
лікуванні хворих на інфаркт міокарда з серцевою недостатністю. Показано, что при використанні еплеренону більш 
висока вірогідність відновлення функціональних показників міокарда. 
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